Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.

MedStar author(s):
Citation: Journal of Clinical Endocrinology & Metabolism. 98(8):3269-79, 2013 Aug.PMID: 23709654Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: Medicine/EndocrinologyForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov'tSubject headings: *Diabetes Mellitus/dt [Drug Therapy] | *Hypoglycemic Agents/tu [Therapeutic Use] | *Metformin/tu [Therapeutic Use] | *Thyroid Neoplasms/dt [Drug Therapy] | Adult | Aged | Cell Movement/de [Drug Effects] | Cell Proliferation/de [Drug Effects] | Disease-Free Survival | Female | Humans | Immunohistochemistry | Logistic Models | Male | Middle Aged | Oxidative Stress | Proportional Hazards Models | Remission Induction | Thyroid Neoplasms/ch [Chemistry] | Thyroid Neoplasms/mo [Mortality] | Thyroid Neoplasms/pa [Pathology] | Treatment OutcomeISSN:
  • 0021-972X
Name of journal: The Journal of clinical endocrinology and metabolismAbstract: CONCLUSIONS: Tumor size is smaller in patients treated with metformin, suggesting inhibition of tumor growth by the drug. Among diabetics, the absence of metformin therapy is an independent factor for decreased likelihood of CR and increased risk of shorter progression-free survival. In vitro data suggest that p70S6K/pS6 is likely a molecular target of metformin in DTC cells.CONTEXT: Clinical trials demonstrated that metformin increases the efficiency of systemic therapy in cancer patients.DESIGN: We compared the rate of complete response (CR) between diabetics who were treated with metformin (group MF+; n = 34) or not treated (group MF-; n = 21) and control nondiabetic patients (group C; n = 185). We also examined the effects of metformin on DTC cells in vitro.OBJECTIVE: We examined whether the efficacy of conventional treatment of differentiated thyroid cancer (DTC) is affected by therapy with metformin in diabetic patients.RESULTS: The groups were comparable in terms of age, sex, body mass index, diabetes management, frequencies of multifocal tumor growth, extrathyroidal extension, and locoregional and distant metastases. Tumor size was significantly smaller in the MF+ group compared with the MF- and C groups (1.37 + 0.97 vs 2.44 + 1.49 vs 2.39 + 1.73 cm, respectively; P = .026). A multivariate model revealed that extrathyroidal extension (P = .018), distant metastases (P < .0001), and lack of treatment with metformin of diabetics (P < .0001) decreased the likelihood of CR. A Cox hazards model revealed that age (P = .025), locoregional metastases (P = .022), distant metastases (P = .003), and lack of treatment with metformin of patients with diabetes (P = .014) are associated with increased risk for shortened progression-free survival. In vitro data revealed that metformin inhibited cancer cell growth, activated cAMP-inducible protein kinase (5'-AMP-activated protein kinase [AMPK]), and down-regulated p70S6K/pS6. Metformin potentiated H2O2-inducible activation of AMPK but attenuated pERK and p70S6K. Tumors from MF+ patients demonstrated a lower level of phospho-p70S6K compared with the MF- group.All authors: Bauer A, Burman KD, Costello J Jr, Jensen K, Klubo-Gwiezdzinska J, Mete M, Patel A, Vasko V, Wartofsky LDigital Object Identifier: Date added to catalog: 2014-04-22
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 23709654

CONCLUSIONS: Tumor size is smaller in patients treated with metformin, suggesting inhibition of tumor growth by the drug. Among diabetics, the absence of metformin therapy is an independent factor for decreased likelihood of CR and increased risk of shorter progression-free survival. In vitro data suggest that p70S6K/pS6 is likely a molecular target of metformin in DTC cells.

CONTEXT: Clinical trials demonstrated that metformin increases the efficiency of systemic therapy in cancer patients.

DESIGN: We compared the rate of complete response (CR) between diabetics who were treated with metformin (group MF+; n = 34) or not treated (group MF-; n = 21) and control nondiabetic patients (group C; n = 185). We also examined the effects of metformin on DTC cells in vitro.

OBJECTIVE: We examined whether the efficacy of conventional treatment of differentiated thyroid cancer (DTC) is affected by therapy with metformin in diabetic patients.

RESULTS: The groups were comparable in terms of age, sex, body mass index, diabetes management, frequencies of multifocal tumor growth, extrathyroidal extension, and locoregional and distant metastases. Tumor size was significantly smaller in the MF+ group compared with the MF- and C groups (1.37 + 0.97 vs 2.44 + 1.49 vs 2.39 + 1.73 cm, respectively; P = .026). A multivariate model revealed that extrathyroidal extension (P = .018), distant metastases (P < .0001), and lack of treatment with metformin of diabetics (P < .0001) decreased the likelihood of CR. A Cox hazards model revealed that age (P = .025), locoregional metastases (P = .022), distant metastases (P = .003), and lack of treatment with metformin of patients with diabetes (P = .014) are associated with increased risk for shortened progression-free survival. In vitro data revealed that metformin inhibited cancer cell growth, activated cAMP-inducible protein kinase (5'-AMP-activated protein kinase [AMPK]), and down-regulated p70S6K/pS6. Metformin potentiated H2O2-inducible activation of AMPK but attenuated pERK and p70S6K. Tumors from MF+ patients demonstrated a lower level of phospho-p70S6K compared with the MF- group.

Powered by Koha